MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.26
+2.41
+12.14%
Opening 09:35 05/07 EDT
OPEN
23.00
PREV CLOSE
19.85
HIGH
23.28
LOW
22.00
VOLUME
134.52K
TURNOVER
--
52 WEEK HIGH
168.80
52 WEEK LOW
12.32
MARKET CAP
238.14M
P/E (TTM)
-0.2223
1D
5D
1M
3M
1Y
5Y
TLRY, ET, ROKU and NET among premarket gainers
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on
Seekingalpha · 1h ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 1h ago
Oppenheimer Initiates Coverage On Chemomab Therapeutics with Outperform Rating, Announces Price Target of $42
Oppenheimer analyst Jeff Jones initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform rating and announces Price Target of $42.
Benzinga · 2h ago
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 20h ago
64 Biggest Movers From Yesterday
Gainers
Benzinga · 2d ago
Chemomab Therapeutics Files Shelf of Up to $200 Million in Securities
MT Newswires · 4d ago
BRIEF-Chemomab Therapeutics Files For Mixed Shelf Of Up To $200 Mln– SEC Filing
reuters.com · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 04/27 20:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMMB. Analyze the recent business situations of Chemomab Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMMB stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 325.65K
% Owned: 3.04%
Shares Outstanding: 10.70M
TypeInstitutionsShares
Increased
0
0
New
2
8.48K
Decreased
0
0
Sold Out
1
1.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Stephen Squinto
Chief Executive Officer/Chief Scientific Officer/Director
Adi Mor
Chief Financial Officer
Sigal Fattal
Senior Vice President
Ronald Knickerbocker
Vice President
Sean Daly
Vice President - Research & Development
Michal Gilon Ohev-Zion
Other
Aaron Aharon
Other
Joseph Ginossar
Other
David Kerstein
Director
Neil Cohen
Director
Nissim Darvish
Director
Joel Maryles
Director
Alan Moses
Director
Claude Nicaise
Independent Director
Lawrence Howard
No Data
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers kinds of Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ:CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.